(Q33504167)

27 July 2017

1 reference

title

Topotecan. A review of its potential in advanced ovarian cancer (English)

1 reference

27 July 2017

1 reference

1

Brogden RN

1 reference

27 July 2017

Wiseman LR

2

1 reference

27 July 2017

1 October 1998

1 reference

27 July 2017

1 reference

27 July 2017

56

1 reference

27 July 2017

4

1 reference

27 July 2017

709-723

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199856040-00017

27 July 2017

0 references

cites work

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study

1 reference

12 December 2020

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

12 December 2020

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

12 December 2020

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

12 December 2020

In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

1 reference

12 December 2020

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

12 December 2020

Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

1 reference

12 December 2020

Clinical pharmacokinetics of topotecan

1 reference

12 December 2020

In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues

1 reference

12 December 2020

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

1 reference

12 December 2020

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

12 December 2020

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

12 December 2020

Epithelial ovarian carcinoma

1 reference

12 December 2020

Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo

1 reference

12 December 2020

High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma

1 reference

12 December 2020

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

12 December 2020

Clinical, pharmacokinetic and biological studies of topotecan.

1 reference

12 December 2020

Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

1 reference

12 December 2020

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

12 December 2020

NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer

1 reference

12 December 2020

The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs

1 reference

12 December 2020

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

12 December 2020

Preclinical and phase I trials of topoisomerase I inhibitors

1 reference

12 December 2020

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

1 reference

12 December 2020

Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.

1 reference

12 December 2020

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

Advanced epithelial ovarian cancer: 1993 consensus statements

1 reference

12 December 2020

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

1 reference

12 December 2020

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

1 reference

12 December 2020

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

12 December 2020

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1 reference

12 December 2020

Pharmacokinetics and early clinical studies of selected new drugs.

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion

1 reference

12 December 2020

Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine

1 reference

12 December 2020

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

1 reference

12 December 2020

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

12 December 2020

High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.

1 reference

12 December 2020

New therapy for ovarian cancer

1 reference

12 December 2020

Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.

1 reference

12 December 2020

Camptothecins: from bench research to hospital wards.

1 reference

12 December 2020

Current drug treatment guidelines for epithelial ovarian cancer

1 reference

12 December 2020

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

1 reference

12 December 2020

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

12 December 2020

Camptothecin analogues: studies from the Johns Hopkins Oncology Center.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

1 reference

12 December 2020

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

12 December 2020

Schedule-dependent efficacy of camptothecins in models of human cancer

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

1 reference

12 December 2020

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days

1 reference

12 December 2020

10.2165/00003495-199856040-00017

Identifiers

DOI

1 reference

PubMed ID

9806112

Dimensions Publication ID

27 July 2017

0 references

1 reference

PubMed ID

9806112